Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The FDA label includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, with contraindications for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
The reduction of mTORC1 might also led to the decreased glutamine metabolism and Gls1 expression level
This triple activation is not just marketing language
Chem-Us 10:855866
US$ 28.57
US$ 28.81
